Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherArticle

Assessment of the Potential for Veverimer Drug-Drug Interactions

Dawn Parsell, Jun Shao, Robert Guttendorf, Vandana Mathur, Elizabeth Li, Yick Sen Wu, Li Tsao, Scott Tabakman, Yuri Stasiv, Angela Lee, Kalpesh Biyani and Gerrit Klaerner
Drug Metabolism and Disposition May 24, 2021, DMD-AR-2021-000366; DOI: https://doi.org/10.1124/dmd.121.000366
Dawn Parsell
1Tricida, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dparsell@tricida.com
Jun Shao
1Tricida, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Guttendorf
2Aclairo Pharmaceutical Development Group, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vandana Mathur
3MathurConsulting, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Li
4PharmaStat LLC, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yick Sen Wu
1Tricida, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Tsao
1Tricida, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Tabakman
1Tricida, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuri Stasiv
1Tricida, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Lee
1Tricida, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kalpesh Biyani
1Tricida, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerrit Klaerner
1Tricida, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Data Supplement

  • Supplemental Data -

    Mean (SD) Plasma Total Dabigatran Concentration Profile over Time (Linear Scale)Supplemental Methods 

    Supplemental Table 1 - Anionic Probes (Test Acids).

    Supplemental Table 2 - Gastric pH Study Subject Disposition.

    Supplemental Table 3 - Gastric pH Study Demographics and Baseline Characteristics

    Supplemental Table 4 -Test Drugs with pH-Dependent Solubility

    Supplemental Table 5 - Exclusion Criteria for Genotyping

    Supplemental Table 6 - DDI Study Subject Disposition

    Supplemental Table 7 - DDI Study Demographics and Baseline Characteristics

    Supplemental Table 8 - Human DDI Study Pharmacokinetics Analyses - Summary Statistics

    Supplemental Table 9 - Summary Statistics for INR AUC0-0168 and INRmax in the Warfarin DDI Study

    Supplemental Table 10 - ANOVA Comparison of Geometric Least Square Means for INR AUC0-0168 and INRmax in the Warfarin DDI Study

    Supplemental Figure 1 - Gastric pH Study Design Schematic

    Supplemental Figure 2 - Drug-Drug Interaction Study Design (Furosemide, Aspirin, Warfarin)

    Supplemental Figure 3 - Drug-Drug Interaction Study Design (Dabigatran)

    Supplemental Figure 4 - Effect of Food: Water Administered under Fasting vs. Fed Conditions

    Supplemental Figure 5 - Effect of Omeprazole: Water Administered under Fasting Conditions Without vs. With Omeprazole

    Supplemental Figure 6 - Mean (SD) Plasma Furosemide Concentration Profile over Time (Linear Scale)

    Supplemental Figure 7 - Mean Plasma Furosemide Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 8 - Mean (SD) Plasma Acetylsalicylic Acid Concentration Profile over Time (Linear Scale)

    Supplemental Figure 9 - Mean Plasma Acetylsalicylic Acid Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 10 - Mean (SD) Plasma Salicylic Acid Concentration Profile over Time (Linear Scale)

    Supplemental Figure 11 - Mean Plasma Salicylic Acid Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 12 - Mean (SD) Plasma R-Warfarin Concentration Profile over Time (Linear Scale)

    Supplemental Figure 13 - Mean Plasma R-Warfarin Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 14 - Mean (SD) Plasma S-Warfarin Concentration Profile over Time (Linear Scale)

    Supplemental Figure 15 - Mean Plasma S-Warfarin Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 16 - Mean (SD) Plasma Total Dabigatran Concentration Profile over Time (Linear Scale)

    Supplemental Figure 17 - Mean Plasma Total Dabigatran Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 18 - Mean (SD) Plasma Free Dabigatran Concentration Profile over Time (Linear Scale)

    Supplemental Figure 19 - Mean Plasma Free Dabigatran Concentration Profile over Time (Log-Linear Scale)

    Supplemental Figure 20 - Mean (SD) International Normalized Ratio over Time (Linear Scale)

    Supplemental Figure 21 - Mean International Normalized Ratio over Time (Log-Linear Scale)

  View article

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics